At a glance
ClinicalIndex Comparison RecordPhase 2Active· 35 enrolled
Drug / intervention
Defactinib Hydrochloridedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
MATCH Treatment Subprotocol U: VS-6063 (Defactinib) in Patients With Tumors With NF2 Loss
In Brief
A Phase 2 clinical trial evaluating Defactinib Hydrochloride for Advanced Lymphoma and 5 related conditions. Active but no longer recruiting, targeting 35 participants across 1 site.
Detailed Summary
This phase II MATCH treatment trial identifies the effects of VS-6063 (defactinib) in patients whose cancer has a genetic change called NF2 mutation. Defactinib may block a protein called FAK, which may be needed for cancer cell growth when NF2 mutations are present. Researchers hope to learn if defactinib will shrink this type of cancer or stop its growth.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdvanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
CountriesUnited States
Collaborators--
Timeline
Phase 2Active
201620172018201920202021202220232024202520262027
Enrollment StartNov 2015
First PostedJun 2020
Primary CompletionNov 2020
TodayJul 2026
Study CompletionJan 2027
First PostedJun 19, 2020
Enrollment StartNov 19, 2015
Primary CompletionNov 10, 2020
Study CompletionJan 15, 2027
TodayJul 2, 2026
Enrollment to primary: 5.0 yearsPosted 6.0 years ago
Interventions
Defactinib Hydrochloridedrug
Given PO